-- Company optimally positioned to increase market share in highly 
valued Australian hemostat market, following positive feedback 
from physician usage of HEMOBLAST(TM) Bellows

     -- Building on inclusion on the Australian Register of Therapeutic 
Goods (ARTG) and agreed partnership with LHC in 2019

Biom'up France SAS (the "Company"), and its affiliates (together, 
"Biom'up"), a leading developer of hemostatic products used in the 
surgical channel, currently featuring HEMOBLAST(TM) Bellows, continues 
its strong and positive growth trajectory in the Australian market 
following favorable reactions from Australian surgeons regarding the 
efficacy and versatility of HEMOBLAST(TM) Bellows since its initial 
launch in July 2020.

As previously announced, Biom'up signed an exclusive agreement with 
LifeHealthcare, a leading independent distributor of medical devices and 
healthcare solutions in Australia and New Zealand, for the distribution 
of HEMOBLAST(TM) Bellows. The partnership has positioned Biom'up to make 
substantial inroads into the growing Australian market through 
LifeHealthcare's wide commercial footprint in the market. Through this 
platform, the Company's novel hemostatic device has been launched for use 
with an initial focus on spine and cardiac surgeries.

"The introduction of HEMOBLAST(TM) Bellows to the Australian market has 
been a formidable initial success. The results and feedback from the 
physician usage have confirmed our confidence in our product's value-add 
and bodes well for Biom'up's prospects in the Australian market," says 
Patrice Ferrand, Group CEO of Biom'up. "With the total Australian 
hemostat market valued at $59M AUD, of which $35M addressable is 
combination hemostats, there is no doubt that there is a solid role for 
HEMOBLAST(TM) Bellows to play in this market. Our objective remains to 
make our best-in-class product accessible across Australia to as many 
surgeons and patients as possible." 

Inclusion on the ARTG of HEMOBLAST(TM) Bellows was confirmed in May 2020 
by the Therapeutic Goods Administration (TGA) for open as well as 
laparoscopic surgery. 

About Biom'up 

Founded in 2005 and based in the Lyon suburb of Saint-Priest (France), 
Biom'up develops and commercializes hemostatic products based on patented 
biopolymers designed to simplify surgeons' practices for open and 
minimally invasive surgical procedures across multiple specialties such 
as cardiac, general, and orthopedic surgery. The Company's lead product, 
HEMOBLAST(TM) Bellows and its laparoscopic applicator are marketed in 
Europe and the United States.

About HEMOBLAST(TM)

HEMOBLAST(TM) Bellows is a hemostatic product used to control bleeding in 
a broad range of open and minimally invasive surgical procedures, 
including laparoscopy. 

Uncontrolled bleeding is a major surgical complication associated with 
higher mortality, longer hospitalization and higher rates of transfusions 
and reoperations. Beyond its impact on patient's health, this major 
complication causes excess costs in all surgical specialties and is a 
burden for hospital budgets across the globe. HEMOBLAST(TM) Bellows is 
the only surgical hemostatic agent approved by the FDA based on the 
validated SPOT GRADE(TM) Surface Bleeding Severity Scale (SBSS), which 
demonstrates the ability to control a range of bleeding from minimal 
(oozing), mild (pooling) and moderate (flowing) bleeding. HEMOBLAST(TM) 
Bellows is proven to control bleeding with flow rates up to 117 mL per 
minute. Due to its efficacy, versatility and ease of use, HEMOBLAST(TM) 
Bellows is quickly becoming a popular choice amongst U.S. and European 
surgeons looking for new options to control surgical bleeding challenges. 

Media contact:

For the United States:
Daniel Yunger
Kekst CNC
+1 212-521-4800
daniel.yunger@kekstcnc.com 

For France:
Elvira Pignal
Kekst CNC
+33 6 37 23 68 36
elvira.pignal@kekstcnc.com